The United States Anti-Doping Agency announced on Wednesday that Chad Mendes has received a two-year period of ineligibility for violating the UFC Anti-Doping Policy.
Mendes tested positive for GHRP-6 (Growth Hormone-Releasing Hexapeptide) following an out-of-competition drug test conducted on May 17, 2016.
“GHRP-6 is a prohibited substance in the class of Peptide Hormones, Growth Factors, Related Substances and Mimetics under the UFC Anti-Doping Policy, which has adopted the World Anti-Doping Agency (WADA) Prohibited List,” according to a USADA statement.
TRENDING > Brock Lesnar Allegedly Tested Positive for Same Estrogen Blocker as Jon Jones
“Growth Hormone-Releasing Peptides are listed as Non-Specified Substances on the WADA Prohibited List. Under the UFC Anti-Doping Policy, the standard sanction for an anti-doping policy violation involving a Non-Specified Substance is a two-year period of ineligibility.”
Mendes’ two-year period of ineligibility is retroactive to June 10, 2016, the date upon which he received a provisional suspension. According to USADA, Mendes has also been “disqualified from all competitive results obtained on and subsequent to May 17, 2016, the date of sample collection, including forfeiture of any title, ranking, purse or other compensation.”
That doesn’t really effect any results for Mendes, as he hasn’t fought since a knockout loss to Frankie Edgar in The Ultimate Fighter 22 Finale main event on Dec. 11, 2015.
Mendes will be eligible to return to competition on June 10, 2018.